Photocure ASA: Presentation of the fourth quarter and full year 2015 results
February 04, 2016 07:42 ET
|
Photocure ASA
Photocure will present its fourth quarter and full year 2015 report on Thursday 11 February 2016 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives...
Photocure: Presentation at DNB's 6th Annual Health Care Conference in Oslo
December 15, 2015 02:40 ET
|
Photocure ASA
Oslo, Norway, December 15, 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, will present a company overview at DNB's...
Photocure: Visonac® data published in the British Journal of Dermatology
December 14, 2015 03:20 ET
|
Photocure ASA
Phase 2b results demonstrate a significant reduction in inflammatory lesions and a significant improvement in overall acne severity Oslo, Norway, December 14, 2015: Photocure (OSE: PHO), a...
Photocure: New Hexvix®/Cysview® data to be presented during the 16th Annual SUO in Washington DC
December 03, 2015 02:20 ET
|
Photocure ASA
Oslo, Norway, December 3, 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, today announces that new clinical data on...
Photocure ASA: Results for third quarter 2015
October 29, 2015 02:30 ET
|
Photocure ASA
Oslo, Norway, 29 October 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, announces its results for the third quarter...
Photocure ASA: Presentation of the third quarter 2015 results
October 27, 2015 05:27 ET
|
Photocure ASA
Photocure will present its third quarter 2015 report on Thursday 29 October 2015 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company...
Photocure: First patient enrolled in Hexvix®/Cysview® Phase 3 Market Expansion Study
October 02, 2015 02:00 ET
|
Photocure ASA
Oslo, Norway, October 2, 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, today announces that the first patient has...
Photocure announces grant of new European patent for Cevira®
September 22, 2015 02:08 ET
|
Photocure ASA
Oslo, September 22, 2015 - Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology today announces that a new patent for Cevira has...
Photocure ASA: Share capital increase registered
September 16, 2015 09:05 ET
|
Photocure ASA
Reference is made to the announcement on 8 September 2015 in respect of a capital increase of 50 830 new shares following exercise of employee share options in the company. The share capital...
Photocure ASA: Resolved share capital increase in connection with exercise of options
September 08, 2015 02:28 ET
|
Photocure ASA
The board of directors of Photocure ASA has resolved a share capital increase pursuant to employees exercising vested options granted under the company's employee incentive scheme. The company's...